J.-C. Millochau , S. Marret , S. Oden , E. Verspyck
{"title":"鲁昂大学用于神经保护目的的硫酸镁的使用情况","authors":"J.-C. Millochau , S. Marret , S. Oden , E. Verspyck","doi":"10.1016/j.gyobfe.2016.05.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal on very preterm infants has been shown, there is still reluctance to use it. The aim of this study was to conduct an assessment of our practice using magnesium sulfate to prevent cerebral palsy at Rouen University Hospital to report its feasibility and safety in order to spread its use.</p></div><div><h3>Methods</h3><p>Unicentric and retrospective study, at the University Hospital of Rouen, between January and June 2014. All patients who delivered before 33 weeks or considered at risk of imminent delivery before 33 weeks were included (<em>n</em> <!-->=<!--> <!-->86).</p></div><div><h3>Results</h3><p>Among the patients who delivered before 33 weeks (<em>n</em> <!-->=<!--> <!-->82), a magnesium sulfate loading dose was administrated in 91.5% of cases. Treatment was mainly established and monitored by midwives (98.6%), usually in the delivery room (82.4%), and with an average duration of administration of 8.9<!--> <!-->±<!--> <!-->17.5<!--> <!-->hours. The treatment had to be stopped in a patient who presented bradypnea associated with impaired consciousness.</p></div><div><h3>Conclusion</h3><p>Our study shows that magnesium sulfate can easily be prescribed in clinical practice.</p></div>","PeriodicalId":55077,"journal":{"name":"Gynecologie Obstetrique & Fertilite","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gyobfe.2016.05.008","citationCount":"1","resultStr":"{\"title\":\"État des lieux de l’utilisation du sulfate de magnésium à visée neuroprotectrice au CHU de Rouen\",\"authors\":\"J.-C. Millochau , S. Marret , S. Oden , E. Verspyck\",\"doi\":\"10.1016/j.gyobfe.2016.05.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal on very preterm infants has been shown, there is still reluctance to use it. The aim of this study was to conduct an assessment of our practice using magnesium sulfate to prevent cerebral palsy at Rouen University Hospital to report its feasibility and safety in order to spread its use.</p></div><div><h3>Methods</h3><p>Unicentric and retrospective study, at the University Hospital of Rouen, between January and June 2014. All patients who delivered before 33 weeks or considered at risk of imminent delivery before 33 weeks were included (<em>n</em> <!-->=<!--> <!-->86).</p></div><div><h3>Results</h3><p>Among the patients who delivered before 33 weeks (<em>n</em> <!-->=<!--> <!-->82), a magnesium sulfate loading dose was administrated in 91.5% of cases. Treatment was mainly established and monitored by midwives (98.6%), usually in the delivery room (82.4%), and with an average duration of administration of 8.9<!--> <!-->±<!--> <!-->17.5<!--> <!-->hours. The treatment had to be stopped in a patient who presented bradypnea associated with impaired consciousness.</p></div><div><h3>Conclusion</h3><p>Our study shows that magnesium sulfate can easily be prescribed in clinical practice.</p></div>\",\"PeriodicalId\":55077,\"journal\":{\"name\":\"Gynecologie Obstetrique & Fertilite\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.gyobfe.2016.05.008\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologie Obstetrique & Fertilite\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297958916301576\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique & Fertilite","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297958916301576","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
État des lieux de l’utilisation du sulfate de magnésium à visée neuroprotectrice au CHU de Rouen
Objectives
Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal on very preterm infants has been shown, there is still reluctance to use it. The aim of this study was to conduct an assessment of our practice using magnesium sulfate to prevent cerebral palsy at Rouen University Hospital to report its feasibility and safety in order to spread its use.
Methods
Unicentric and retrospective study, at the University Hospital of Rouen, between January and June 2014. All patients who delivered before 33 weeks or considered at risk of imminent delivery before 33 weeks were included (n = 86).
Results
Among the patients who delivered before 33 weeks (n = 82), a magnesium sulfate loading dose was administrated in 91.5% of cases. Treatment was mainly established and monitored by midwives (98.6%), usually in the delivery room (82.4%), and with an average duration of administration of 8.9 ± 17.5 hours. The treatment had to be stopped in a patient who presented bradypnea associated with impaired consciousness.
Conclusion
Our study shows that magnesium sulfate can easily be prescribed in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
